Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia

Clinical Endocrinology

Volumn 46, Issue 2, 1997, Pages 137-144

  Habib, Fouad K ^a   Ross, Margaret ^a   Tate, Rothwell ^a   Chisholm, Geoffrey D ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; FINASTERIDE; OXIDOREDUCTASE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; HUMAN; HYPERPLASIA; MALE; PRIORITY JOURNAL; PROSTATE; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TRANSURETHRAL RESECTION;

EID: 0030951381     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1997.950908.x     Document Type: Article

References (27)

1. Andersson, S., Berman, D.M., Jenkins, E.P. & Russell, D.W. (1991) Deletion of steroid 5 alpha-reductase to gene in male pseudohermaphroditism. Nature, 354, 159-161.
2. Bonnet, P., Reiter, E., Bruyninx, M., Sente, B., Dombrowicz, D., de Levai, J., Closset, J. & Hennen, G. (1993) Benign prostatic hyperplasia and normal prostate aging: Differences in types I and II 5 alpha reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels. Journal of Clinical Endocrinology and Metabolism, 77, 1203-1208.
3. Bradford, M.M. (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle protein di-binding. Analytical Biochemistry, 72, 248-254.
4. Bruchovsky, N. & Lieskovski, G. (1979) Increased rates of 5-alpha-reductase: 3alpha/(beta) hydroxysteroid dehydrogenase activities in the hyperplastic human prostate. Journal of Endocrinology, 80, 289-301.
5. Geller, J. (1990) The effect of Finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate specific antigens. Journal of Clinical Endocrinology and Metabolism, 71, 1552-1555.
6. Gormley, G.J., Stoner, E., Bruskewitz, R.C., Imperato-McGinley, J., Walsh, P.C., McConnell, J.D., Andriole, G.L., Geller, J., Bracken, B.R., Tenover, J.S., Vaughan, E.D., Pappas, F., Taylor, A., Binko-witz, B. & Ng, J. (1992) The effect of Finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine, 327, 1185-1191.
7. Guess, H.A., Heyse, J.F. & Gormley, G.T. (1993) The effect of Finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate, 22, 31-37.
8. Habib, F.K. (1990) Prostate mechanisms of normal and abnormal metabolism. In: Scientific Foundations of Urology (eds. G.D. Chisholm & W.R. Fair), pp. 358-365, Wm Heinemann Medical Book, London.
9. Habib, F.K. (1994) Pathogenesis of benign prostatic hyperplasia. In Handbook on Benign Prostatic Hyperplasia (ed. G.D. Chisholm), pp. 19-31, Raven Press, New York.
10. Habib, F.K., Lee, I.R., Stitch, S.R. & Smith, P.H. (1976) Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate. Journal of Endocrinology, 71, 99-107.
11. Habib, F.K., Mason, M.K., Smith, P.H. & Stitch, S.R. (1979) Cancer of the prostate: Early diagnosis by zinc and hormonal analysis. British Journal of Cancer, 39, 700-704.
12. Habib, F.K., Ross, M., Bayne, C.W., Grigor, K., Buck, A.C., Bollina, P. & Chapman, K. (1997) The localization and expression of 5α-reductase type I and II mRNA's in human hyperplastic prostate and in prostate primary cultures. Journal of Endocrinology (in press).
13. Habib, F.K., Smith, T., Robinson, Rosemary & Chisholm, G.D. (1985) Influence of surgical techniques on receptor levels and 5 alpha-reductase activity of the human prostate gland. Prostate, 7, 287-292.
14. Hirsch, K.S., Jones, C.D., Audia, J.E., Andersson, S., McQuaid, L., Stamm, N.B., Neubauer, B.L., Pennington, P., Toomey, R.E. & Russell, D.W. (1993) LY191704: A selective, non-steroidal inhibitor of human steroid 5alpha reductase type I. Proceedings of the National Academy of Science USA, 90, 5277-5281.
15. Houston, B., Chisholm, G.D. & Habib, F.K. (1985) Solubilization of human prostatic 5 alpha reductase. Journal of Steroid Biochemistry, 22, 461-467.
16. Imperato-McGinley, J., Gautier, T., Zirinsky, K., Hom, T., Palomo, O., Stein, E., Vaughan, E.D., Markisz, J.A., de Arellano, E.R. & Kazam, E. (1992) Prostate visualisation studies in males homozygous and heterozygous for 5 alpha reductase deficiency. Journal of Clinical Endocrinology and Metabolism, 75, 1022-1026.
17. Isaacs, J.T., Brendler, C.B. & Walsh, P.C. (1983) Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. Journal of Clinical Endocrinology and Metabolism, 56, 139-145.
18. Kirby, R.S., Bryan, J. & Earlie, I. (1992) Finasteride in the treatment of benign prostatic hyperplasia. Urodynamic evaluation. British Journal of Urology, 20, 65-72.
19. Mcconnell, J.D., Wilson, J.D., George, F.W., Geller, J., Pappas, F. & Stoner, E. (1992) Finasteride, an inhibitor of 5 alpha reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. Journal of Clinical Endocrinology and Metabolism, 74, 505-508.
20. Norman, R.W., Coakes, K.E., Stuart-Wright, A. & Rittmaster, R.S. (1993) Androgen metabolism in men receiving Finasteride before prostatectomy. Journal of Urology, 150, 1736-1739.
21. Rennie, P.S., Bruchovsky, N., McLoughlin, M.G., Batold, F.H. & Dunstan-Adams, E. (1983) Kinetic analysis of 5 alpha reductase isoenzymes in benign prostatic hyperplasia (BPH). Journal of Steroid Biochemistry, 19, 169-173.
22. Russell, D.W. & Wilson, J.D. (1994) Steroid 5 alpha-reductase: two genes/two enzymes. Annual Review of Biochemistry, 63, 25-61.
23. Schroder, F.H., Westerhof, M., Bosch, R.J.L.H. & Kurth, K.H. (1986) Benign prostatic hyperplasia treated by castration or the LHRH analogue buserelin: A report on 6 cases. European Urology, 12, 318-321.
24. Silver, R.I., Wiley, E.L., Davis, D.L., Thigpen, A.E., Russell, D.W. & McConnell, J.D. (1994) Expression and regulation of steroid-5 alpha-reductase-2 in prostate disease. Journal of Urology, 152, 433-437.
25. Walsh, P.C. (1986) Benign prostatic hyperplasia. In Campbells Urology, (ed. P.C. Walsh), pp. 1248-1265, W.B. Saunders, Philadelphia.
26. Walsh, P.C., Hutchins, G.M. & Ewing, L.L. (1983) tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranomal. Journal of Clinical Investigation, 72, 1772-1777.
27. Yang, Y., Chisholm, G.D. & Habib, F.K. (1992) The distribution of PSA, Cathepsin-D and pS2 in BPH and cancer of the prostate. Prostate, 21, 201-208.